Oncological treatment effect of head and neck cancer on auditory system
Autor(a) principal: | |
---|---|
Data de Publicação: | 2022 |
Outros Autores: | , , , , |
Tipo de documento: | Artigo |
Idioma: | por |
Título da fonte: | Research, Society and Development |
Texto Completo: | https://rsdjournal.org/index.php/rsd/article/view/25209 |
Resumo: | Introduction: The improvement in the quality of life of patients with head and neck cancer has been the subject of studies, however hearing loss is one of the side effects of cancer treatment that significantly affect the quality of life of its patient, especially when radiotherapy is performed combined with cisplatin. Objective: To analyze the audiological findings of participants with head and neck cancer who underwent radiotherapy alone and concomitantly with cisplatin. Methodology: Participants with anatomopathological diagnosis of cancer of the head and neck who were at the end of cancer treatment, with normal hearing threshold prior to anticancer treatment, were included. Two groups were listed: Radiotherapy (RT) and chemotherapy concomitant with radiotherapy (QTRT). The QTRT participants used cisplatin, a drug from the Platinum Group at a dose between 200 and 300mg. Among the procedures performed are: anamnesis, otoscopy and conventional pure tone audiometry. Results: 22 subjects participated, with a mean age of 48.48 years, mostly men (68.2%). It was found that 59.1% had sensorineural hearing loss. The RT group consisted of 10 participants, 25% reported tinnitus and 38.5% were diagnosed with hearing loss. The QTRT with 12 participants reported tinnitus (25%) and 61.5% developed hearing loss. There was no statistically significant difference between groups for hearing thresholds in the frequencies under test. Conclusion: Patients undergoing antineoplastic treatment had significant side effects related to the hearing organ, and for treatment with concomitant chemotherapy and radiotherapy, the presence of hearing loss was significant. |
id |
UNIFEI_80651633e94a81f5867d7f96d9ba1291 |
---|---|
oai_identifier_str |
oai:ojs.pkp.sfu.ca:article/25209 |
network_acronym_str |
UNIFEI |
network_name_str |
Research, Society and Development |
repository_id_str |
|
spelling |
Oncological treatment effect of head and neck cancer on auditory systemEfecto del tratamiento oncológico del cancer de cabeza y cuello sobre el sistema auditivoEfeito do tratamento oncológico do câncer de cabeça e pescoço no sistema auditivo Head and neck neoplasmsRadiotherapyDrug therapyHaring loss.Neoplasias de cabeza y cuelloRadioterapiaQuimioterapiaPérdida auditiva.Neoplasias de cabeça e pescoçoRadioterapiaQuimioterapiaPerda auditiva.Introduction: The improvement in the quality of life of patients with head and neck cancer has been the subject of studies, however hearing loss is one of the side effects of cancer treatment that significantly affect the quality of life of its patient, especially when radiotherapy is performed combined with cisplatin. Objective: To analyze the audiological findings of participants with head and neck cancer who underwent radiotherapy alone and concomitantly with cisplatin. Methodology: Participants with anatomopathological diagnosis of cancer of the head and neck who were at the end of cancer treatment, with normal hearing threshold prior to anticancer treatment, were included. Two groups were listed: Radiotherapy (RT) and chemotherapy concomitant with radiotherapy (QTRT). The QTRT participants used cisplatin, a drug from the Platinum Group at a dose between 200 and 300mg. Among the procedures performed are: anamnesis, otoscopy and conventional pure tone audiometry. Results: 22 subjects participated, with a mean age of 48.48 years, mostly men (68.2%). It was found that 59.1% had sensorineural hearing loss. The RT group consisted of 10 participants, 25% reported tinnitus and 38.5% were diagnosed with hearing loss. The QTRT with 12 participants reported tinnitus (25%) and 61.5% developed hearing loss. There was no statistically significant difference between groups for hearing thresholds in the frequencies under test. Conclusion: Patients undergoing antineoplastic treatment had significant side effects related to the hearing organ, and for treatment with concomitant chemotherapy and radiotherapy, the presence of hearing loss was significant.Introducción: La mejora en la calidad de vida de los pacientes con cáncer de cabeza y cuello ha sido objeto de estudios, sin embargo la hipoacusia es uno de los efectos secundarios del tratamiento oncológico que afecta significativamente la calidad de vida de su paciente, especialmente cuando se trata de radioterapia. realizado combinado con cisplatino. Objetivo: Analizar los hallazgos audiológicos de participantes con cáncer de cabeza y cuello que recibieron radioterapia sola y concomitantemente con cisplatino. Metodología: Se incluyeron participantes con diagnóstico anatomopatológico de cáncer de cabeza y cuello que se encontraban al final del tratamiento oncológico, con umbral auditivo normal previo al tratamiento antineoplásico. Se enumeraron dos grupos: radioterapia (RT) y quimioterapia concomitante con radioterapia (QTRT). Los participantes del QTRT usaron cisplatino, un medicamento del Grupo Platino en una dosis entre 200 y 300 mg. Entre los procedimientos realizados se encuentran: anamnesis, otoscopia y audiometría convencional de tonos puros. Resultados: participaron 22 sujetos, con una edad media de 48,48 años, en su mayoría hombres (68,2%). Se encontró que el 59,1% presentaba hipoacusia neurosensorial. El grupo de RT estaba formado por 10 participantes, el 25% informó acúfenos y el 38,5% fueron diagnosticados con pérdida auditiva. El QTRT con 12 participantes informó acúfenos (25%) y el 61,5% desarrolló pérdida auditiva. No hubo diferencias estadísticamente significativas entre los grupos para los umbrales de audición en las frecuencias bajo prueba. Conclusión: Los pacientes sometidos a tratamiento antineoplásico presentaron efectos secundarios importantes relacionados con el órgano auditivo, y para el tratamiento con quimioterapia y radioterapia concomitantes, la presencia de hipoacusia fue significativa.Introdução: A melhoria na qualidade de vida dos pacientes com câncer de cabeça e pescoço tem sido alvo de estudos, entretanto a perda auditiva é um dos efeitos colaterais do tratamento oncológico e afetam significativamente a qualidade de vida do seu portador, principalmente quando é realizada radioterapia combinada com cisplatina. Objetivo: Analisar os achados audiológicos de participantes com câncer de cabeça e pescoço submetidos ao tratamento radioterápico isolado e concomitante a cisplatina. Metodologia: Foram incluídos participantes com diagnóstico anatomopatológico de neoplasia de câncer de cabeça e pescoço que estivessem no final do tratamento oncológico, com limiar auditivo normal prévio ao tratamento antioneoplásico. Dois grupos foram elencados: radioterapia (RT) e quimioterapia concomitante a radioterapia (QTRT). Os participantes do QTRT fizeram uso da cisplatina, droga do grupo da platina com dose entre 200 e 300mg. Foram realizados os seguintes procedimentos: anamnese, meatoscopia e audiometria tonal convencional. Resultados: Participaram 22 sujeitos com média de idade de 48,48 anos, na maioria homens (68,2%). Verificou-se que 59,1% apresentaram perda auditiva sensorioneural. O grupo RT foi composto por 10 participantes, 25% relatou zumbido e 38,5% foram diagnosticados com perda auditiva. O QTRT com 12 participantes relatou zumbido (25%) e 61,5% desenvolveram perda auditiva. Não foi observada diferença estatisticamente significativa entre os grupos para os limiares auditivos nas frequências sob teste. Conclusão: Os pacientes submetidos ao tratamento antineoplásico cursaram com efeitos colaterais significativos relacionados ao órgão da audição, sendo que para o tratamento com quimioterapia e radioterapia concomitante foi significativa a presença de perda auditiva.Research, Society and Development2022-01-15info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://rsdjournal.org/index.php/rsd/article/view/2520910.33448/rsd-v11i1.25209Research, Society and Development; Vol. 11 No. 1; e56611125209Research, Society and Development; Vol. 11 Núm. 1; e56611125209Research, Society and Development; v. 11 n. 1; e566111252092525-3409reponame:Research, Society and Developmentinstname:Universidade Federal de Itajubá (UNIFEI)instacron:UNIFEIporhttps://rsdjournal.org/index.php/rsd/article/view/25209/22198Copyright (c) 2022 Priscila Feliciano de Oliveira; Amanda Souza de Jesus ; Lucas Araujo Reis; Tamara Figueiredo do Carmo Santos; Gregorina Silva Ribeiro Rocha; Aline Cabral de Oliveirahttps://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccessOliveira, Priscila Feliciano de Jesus , Amanda Souza de Reis, Lucas Araujo Santos, Tamara Figueiredo do Carmo Rocha, Gregorina Silva Ribeiro Oliveira, Aline Cabral de 2022-01-16T18:08:18Zoai:ojs.pkp.sfu.ca:article/25209Revistahttps://rsdjournal.org/index.php/rsd/indexPUBhttps://rsdjournal.org/index.php/rsd/oairsd.articles@gmail.com2525-34092525-3409opendoar:2024-01-17T09:43:32.913032Research, Society and Development - Universidade Federal de Itajubá (UNIFEI)false |
dc.title.none.fl_str_mv |
Oncological treatment effect of head and neck cancer on auditory system Efecto del tratamiento oncológico del cancer de cabeza y cuello sobre el sistema auditivo Efeito do tratamento oncológico do câncer de cabeça e pescoço no sistema auditivo |
title |
Oncological treatment effect of head and neck cancer on auditory system |
spellingShingle |
Oncological treatment effect of head and neck cancer on auditory system Oliveira, Priscila Feliciano de Head and neck neoplasms Radiotherapy Drug therapy Haring loss. Neoplasias de cabeza y cuello Radioterapia Quimioterapia Pérdida auditiva. Neoplasias de cabeça e pescoço Radioterapia Quimioterapia Perda auditiva. |
title_short |
Oncological treatment effect of head and neck cancer on auditory system |
title_full |
Oncological treatment effect of head and neck cancer on auditory system |
title_fullStr |
Oncological treatment effect of head and neck cancer on auditory system |
title_full_unstemmed |
Oncological treatment effect of head and neck cancer on auditory system |
title_sort |
Oncological treatment effect of head and neck cancer on auditory system |
author |
Oliveira, Priscila Feliciano de |
author_facet |
Oliveira, Priscila Feliciano de Jesus , Amanda Souza de Reis, Lucas Araujo Santos, Tamara Figueiredo do Carmo Rocha, Gregorina Silva Ribeiro Oliveira, Aline Cabral de |
author_role |
author |
author2 |
Jesus , Amanda Souza de Reis, Lucas Araujo Santos, Tamara Figueiredo do Carmo Rocha, Gregorina Silva Ribeiro Oliveira, Aline Cabral de |
author2_role |
author author author author author |
dc.contributor.author.fl_str_mv |
Oliveira, Priscila Feliciano de Jesus , Amanda Souza de Reis, Lucas Araujo Santos, Tamara Figueiredo do Carmo Rocha, Gregorina Silva Ribeiro Oliveira, Aline Cabral de |
dc.subject.por.fl_str_mv |
Head and neck neoplasms Radiotherapy Drug therapy Haring loss. Neoplasias de cabeza y cuello Radioterapia Quimioterapia Pérdida auditiva. Neoplasias de cabeça e pescoço Radioterapia Quimioterapia Perda auditiva. |
topic |
Head and neck neoplasms Radiotherapy Drug therapy Haring loss. Neoplasias de cabeza y cuello Radioterapia Quimioterapia Pérdida auditiva. Neoplasias de cabeça e pescoço Radioterapia Quimioterapia Perda auditiva. |
description |
Introduction: The improvement in the quality of life of patients with head and neck cancer has been the subject of studies, however hearing loss is one of the side effects of cancer treatment that significantly affect the quality of life of its patient, especially when radiotherapy is performed combined with cisplatin. Objective: To analyze the audiological findings of participants with head and neck cancer who underwent radiotherapy alone and concomitantly with cisplatin. Methodology: Participants with anatomopathological diagnosis of cancer of the head and neck who were at the end of cancer treatment, with normal hearing threshold prior to anticancer treatment, were included. Two groups were listed: Radiotherapy (RT) and chemotherapy concomitant with radiotherapy (QTRT). The QTRT participants used cisplatin, a drug from the Platinum Group at a dose between 200 and 300mg. Among the procedures performed are: anamnesis, otoscopy and conventional pure tone audiometry. Results: 22 subjects participated, with a mean age of 48.48 years, mostly men (68.2%). It was found that 59.1% had sensorineural hearing loss. The RT group consisted of 10 participants, 25% reported tinnitus and 38.5% were diagnosed with hearing loss. The QTRT with 12 participants reported tinnitus (25%) and 61.5% developed hearing loss. There was no statistically significant difference between groups for hearing thresholds in the frequencies under test. Conclusion: Patients undergoing antineoplastic treatment had significant side effects related to the hearing organ, and for treatment with concomitant chemotherapy and radiotherapy, the presence of hearing loss was significant. |
publishDate |
2022 |
dc.date.none.fl_str_mv |
2022-01-15 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://rsdjournal.org/index.php/rsd/article/view/25209 10.33448/rsd-v11i1.25209 |
url |
https://rsdjournal.org/index.php/rsd/article/view/25209 |
identifier_str_mv |
10.33448/rsd-v11i1.25209 |
dc.language.iso.fl_str_mv |
por |
language |
por |
dc.relation.none.fl_str_mv |
https://rsdjournal.org/index.php/rsd/article/view/25209/22198 |
dc.rights.driver.fl_str_mv |
https://creativecommons.org/licenses/by/4.0 info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
https://creativecommons.org/licenses/by/4.0 |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Research, Society and Development |
publisher.none.fl_str_mv |
Research, Society and Development |
dc.source.none.fl_str_mv |
Research, Society and Development; Vol. 11 No. 1; e56611125209 Research, Society and Development; Vol. 11 Núm. 1; e56611125209 Research, Society and Development; v. 11 n. 1; e56611125209 2525-3409 reponame:Research, Society and Development instname:Universidade Federal de Itajubá (UNIFEI) instacron:UNIFEI |
instname_str |
Universidade Federal de Itajubá (UNIFEI) |
instacron_str |
UNIFEI |
institution |
UNIFEI |
reponame_str |
Research, Society and Development |
collection |
Research, Society and Development |
repository.name.fl_str_mv |
Research, Society and Development - Universidade Federal de Itajubá (UNIFEI) |
repository.mail.fl_str_mv |
rsd.articles@gmail.com |
_version_ |
1797052761411420160 |